VIVUS, Inc. (NASDAQ:VVUS) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday.

Separately, Zacks Investment Research lowered shares of VIVUS from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 4th.

Shares of VIVUS (NASDAQ VVUS) traded up 0.9207% on Friday, reaching $0.8988. 968,769 shares of the company’s stock were exchanged. VIVUS has a 12 month low of $0.87 and a 12 month high of $1.47. The company has a market cap of $95.10 million, a price-to-earnings ratio of 2.8994 and a beta of 0.86. The firm’s 50-day moving average price is $1.06 and its 200 day moving average price is $1.10.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/vivus-inc-vvus-downgraded-by-valuengine/1536917.html.

Several hedge funds and other institutional investors have recently made changes to their positions in VVUS. IHT Wealth Management LLC raised its position in shares of VIVUS by 653.3% in the second quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 980 shares during the last quarter. Spark Investment Management LLC acquired a new position in shares of VIVUS during the second quarter worth about $100,000. Nine Chapters Capital Management LLC acquired a new position in shares of VIVUS during the first quarter worth about $113,000. Bank of New York Mellon Corp raised its position in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 3,694 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of VIVUS by 84.8% in the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 68,200 shares during the last quarter. Hedge funds and other institutional investors own 35.82% of the company’s stock.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.